Finanzen von Retension Pharmaceuticals, Inc. Common Stock (RTSN)RTSNRetension Pharmaceuticals, Inc. Common Stock

In the context of the broader market, RTSN competes directly with industry leaders such as GNLX and LENZ. With a market capitalization of $84.47M, it holds a significant position in the sector. When comparing efficiency, RTSN's gross margin of N/A stands against GNLX's N/A and LENZ's 86.58%. Such benchmarking helps identify whether Retension Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

Retension Pharmaceuticals has shown consistent losses, with net income decreasing each quarter, culminating in a loss of $4,170,589 in Q2 2026. The current ratio is strong at 5.61, indicating good short-term liquidity, but the total equity has decreased significantly from $14,970,683 in Q1 2026 to $13,251,898 in Q2 2026, reflecting a deteriorating financial position.